-
1
-
-
35648968328
-
-
Accessed July 9, 2007
-
http://www.americanheart.org. Accessed July 9, 2007.
-
-
-
-
2
-
-
33750207033
-
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
-
Kastelein, J., Wedel, M., Baker, B. et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114(16): 1729-35.
-
(2006)
Circulation
, vol.114
, Issue.16
, pp. 1729-1735
-
-
Kastelein, J.1
Wedel, M.2
Baker, B.3
-
3
-
-
0033827087
-
Apolipoprotein B: MRNA editing, lipoprotein assembly, and presecretory degradation
-
Davidson, N.O., Shelness, G.S. Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000, 20: 169-93.
-
(2000)
Annu Rev Nutr
, vol.20
, pp. 169-193
-
-
Davidson, N.O.1
Shelness, G.S.2
-
4
-
-
33847338002
-
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
-
Yu, R., Kim, T.-W., Hong, A., Watanabe, T.A., Gaus, H.J., Geary, R.S. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 2007, 35(3): 460-8.
-
(2007)
Drug Metab Dispos
, vol.35
, Issue.3
, pp. 460-468
-
-
Yu, R.1
Kim, T.-W.2
Hong, A.3
Watanabe, T.A.4
Gaus, H.J.5
Geary, R.S.6
-
5
-
-
35648940976
-
-
Graham, M.J., Lemonidis, K.M., Whipple, C., Petinos, N., Crooke, R.M. Inhibition of human apoB-100 in transgenic mice. Circulation [76th Am Heart Assoc Sci Sess (Nov 9-12, Orlando) 2003] 2003, 108(17, Suppl. 4): Abst 836.
-
Graham, M.J., Lemonidis, K.M., Whipple, C., Petinos, N., Crooke, R.M. Inhibition of human apoB-100 in transgenic mice. Circulation [76th Am Heart Assoc Sci Sess (Nov 9-12, Orlando) 2003] 2003, 108(17, Suppl. 4): Abst 836.
-
-
-
-
6
-
-
33750028350
-
A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient mice expressing a human apoB-100 transgene
-
June 18-22, Rome, Abst Th-W49
-
Chuang, E., Lemonidis, K.M., Whipple, C., Graham, M.J., York-Defalco, C., Hung, G., Crooke, R.M. A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient mice expressing a human apoB-100 transgene. Atherosclerosis Suppl [14th Int Symp Atherosclerosis (June 18-22, Rome) 2006] 2006, 7(3): Abst Th-W49:5.
-
(2006)
Atherosclerosis Suppl [14th Int Symp Atherosclerosis
, vol.7
, Issue.3
, pp. 5
-
-
Chuang, E.1
Lemonidis, K.M.2
Whipple, C.3
Graham, M.J.4
York-Defalco, C.5
Hung, G.6
Crooke, R.M.7
-
7
-
-
35649023932
-
A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient, human apolipoprotein B-100 transgenic mice
-
April 27-29, Denver, Abst 2
-
Lemonidis, K.M., Whipple, C.P., Graham, M.J., Suramaniam, A., York-Defalco, C., Hung, G., Crooke, R.M. A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient, human apolipoprotein B-100 transgenic mice. 7th Annu Conf Arterioscler Thromb Vasc Biol (April 27-29, Denver) 2006, Abst 2.
-
(2006)
7th Annu Conf Arterioscler Thromb Vasc Biol
-
-
Lemonidis, K.M.1
Whipple, C.P.2
Graham, M.J.3
Suramaniam, A.4
York-Defalco, C.5
Hung, G.6
Crooke, R.M.7
-
8
-
-
35648950188
-
Cross-species pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human apoB-100
-
Nov 6-10, Nashville, Abst T3306
-
Yu, R., Geary, R., Kim, T.-W., Cheung, E., Levin, A. Cross-species pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human apoB-100. Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 6-10, Nashville) 2005, Abst T3306.
-
(2005)
Annu Meet Am Assoc Pharm Sci (AAPS)
-
-
Yu, R.1
Geary, R.2
Kim, T.-W.3
Cheung, E.4
Levin, A.5
-
9
-
-
84878727268
-
Pharmacokinetics and tolerability of daily oral antisense oligonucleotide, ISIS 301212, in mice and dog for 13 weeks
-
Nov 6-10, Nashville, Abst T3305
-
Geary, R., Yu, R., Kim, T.-W., Levin, A., Dokka, S., Tillman, L., Hardee, G. Pharmacokinetics and tolerability of daily oral antisense oligonucleotide, ISIS 301212, in mice and dog for 13 weeks. Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 6-10, Nashville) 2005, Abst T3305.
-
(2005)
Annu Meet Am Assoc Pharm Sci (AAPS)
-
-
Geary, R.1
Yu, R.2
Kim, T.-W.3
Levin, A.4
Dokka, S.5
Tillman, L.6
Hardee, G.7
-
10
-
-
35648947573
-
Pharmacokinetic/pharmacodynamic (PK/PD) modeling and dose regimen simulations to guide dose selection in phase 2a of an antisense oligonucleotide, targeting human apoB, in hypercholesterolemia subjects
-
Sept 17-19, Cambridge, Abst 33
-
Yu, R.Z., Geary, R.S., Bradley, J., Chuang, E., Wedel, M., Fuhr, R. Pharmacokinetic/pharmacodynamic (PK/PD) modeling and dose regimen simulations to guide dose selection in phase 2a of an antisense oligonucleotide, targeting human apoB, in hypercholesterolemia subjects. 35th Annu Meet Am Coll Clin Pharmacol (ACCP) (Sept 17-19, Cambridge), 2006, Abst 33.
-
(2006)
35th Annu Meet Am Coll Clin Pharmacol (ACCP)
-
-
Yu, R.Z.1
Geary, R.S.2
Bradley, J.3
Chuang, E.4
Wedel, M.5
Fuhr, R.6
-
11
-
-
33750015093
-
Significant reduction of small dense LDL-cholesterol concentrations in healthy volunteers by antisense inhibition of apolipoprotein B
-
June 18-22, Rome, Abst Th-W49
-
Kastelein, J., Wedel, M.K., Baker, B., Su, J., Bradley, J., Chuang, E. Significant reduction of small dense LDL-cholesterol concentrations in healthy volunteers by antisense inhibition of apolipoprotein B. Atherosclerosis Suppl [14th Int Symp Atherosclerosis (June 18-22, Rome) 2006] 2006, 7(3): Abst Th-W49:6.
-
(2006)
Atherosclerosis Suppl [14th Int Symp Atherosclerosis
, vol.7
, Issue.3
, pp. 6
-
-
Kastelein, J.1
Wedel, M.K.2
Baker, B.3
Su, J.4
Bradley, J.5
Chuang, E.6
-
12
-
-
35648965420
-
-
Bradley, J., Crooke, R., Graham, M., Wedel, M. Small, dense, LDL particle concentration is significantly reduced after treatment with an antisense inhibitor of apoB in healthy volunteers. Circulation [78th Am Heart Assoc Sci Sess (Nov 13-16, Dallas) 2005] 2005, 112(17, Suppl. 2): Abst 727.
-
Bradley, J., Crooke, R., Graham, M., Wedel, M. Small, dense, LDL particle concentration is significantly reduced after treatment with an antisense inhibitor of apoB in healthy volunteers. Circulation [78th Am Heart Assoc Sci Sess (Nov 13-16, Dallas) 2005] 2005, 112(17, Suppl. 2): Abst 727.
-
-
-
-
13
-
-
33750022698
-
Hypolipidemic effects of a novel inhibitor of human apoB-100 in humans
-
June 10-14, San Diego, Abst 977-P
-
Bradley, J., Crooke, R., Kjems, L.L. et al. Hypolipidemic effects of a novel inhibitor of human apoB-100 in humans. 65th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 10-14, San Diego) 2005, Abst 977-P.
-
(2005)
65th Annu Meet Sci Sess Am Diabetes Assoc (ADA)
-
-
Bradley, J.1
Crooke, R.2
Kjems, L.L.3
-
14
-
-
33044499010
-
Evaluation of ISIS 301012, an antisense inhibitor to human apoB 100, in healthy volunteers
-
Oct 24-27, Venice
-
Bradley, J.D., Graham, M., Henry, S., Kim, T-M., Crooke, R., Yu, R., de Haan, H. Evaluation of ISIS 301012, an antisense inhibitor to human apoB 100, in healthy volunteers. 15th Int Symp Drugs Affect Lipid Metab (Oct 24-27, Venice) 2004, 37.
-
(2004)
15th Int Symp Drugs Affect Lipid Metab
, pp. 37
-
-
Bradley, J.D.1
Graham, M.2
Henry, S.3
Kim, T.-M.4
Crooke, R.5
Yu, R.6
de Haan, H.7
-
15
-
-
33750002079
-
Effect of dose and dose schedule on the efficacy and safety of an antisense inhibitor of apoB in volunteers with mild hypercholesterolemia
-
June 18-22, Rome, Abst Th-P16
-
Kastelein, J.J.P., Bradley, J., Chuang, E., Wedel, M.W., Su, J., Geary, R., Yu, R. Effect of dose and dose schedule on the efficacy and safety of an antisense inhibitor of apoB in volunteers with mild hypercholesterolemia. Atherosclerosis Suppl [14th Int Symp Atherosclerosis (June 18-22, Rome) 2006] 2006, 7(3): Abst Th-P16:268.
-
(2006)
Atherosclerosis Suppl [14th Int Symp Atherosclerosis
, vol.7
, Issue.3
, pp. 268
-
-
Kastelein, J.J.P.1
Bradley, J.2
Chuang, E.3
Wedel, M.W.4
Su, J.5
Geary, R.6
Yu, R.7
|